Paradigm Biocapital Advisors LP
NEW YORK, NY · CIK 1855655 · 13F filing filed 2022-02-14
SEC-registered investment adviser since 2021 · limited partnership
- Assets managed$4.5bn
- Staff11 · 6 in investment roles
- Main clients (by assets)Private funds 90%
- Private funds2 (2 hedge) · $4.1bn gross assets
- Form ADV · 2026-08-27SEC adviser record
- Legal entityPARADIGM BIOCAPITAL ADVISORS LP (US)
- Kindhedge funds, futures
- Others nearbyNew York, NY
As an employer
- Offices in1 country
- Private fundshedge 2
$350.2m
reported value
24positions
67.0%in top 10
—no comparable previous quarter
Holdings, Q4 2021
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| MIRATI THERAPEUTICS INC MRTX | $38.2m10.90% | First filing |
| ASCENDIS PHARMA A/S SPONSORED ADR | $29.3m8.38% | First filing |
| ZENTALIS PHARMACEUTICALS INC ZNTL | $25.3m7.21% | First filing |
| VIRIDIAN THERAPEUTICS INC VRDN | $23.9m6.83% | First filing |
| ARENA PHARMACEUTICALS INC ARNA | $23.4m6.68% | First filing |
| GLOBAL BLOOD THERAPEUTICS IN GBT | $22.8m6.52% | First filing |
| ARVINAS INC ARVN | $22.1m6.30% | First filing |
| LEGEND BIOTECH CORP LEGN | $18.0m5.14% | First filing |
| IOVANCE BIOTHERAPEUTICS INC IOVA | $16.1m4.60% | First filing |
| SEAGEN INC SGEN | $15.6m4.45% | First filing |
| ARGENX SE ARGX | $14.7m4.21% | First filing |
| IVERIC BIO INC OPHT | $13.6m3.89% | First filing |
| INSMED INC INSM | $10.7m3.07% | First filing |
| SIERRA ONCOLOGY INC COM NEW | $10.3m2.95% | First filing |
| SYNDAX PHARMACEUTICALS INC SNDX | $9.9m2.83% | First filing |
| GALAPAGOS NV LKFT | $9.3m2.64% | First filing |
| C4 THERAPEUTICS INC CCCC | $8.3m2.38% | First filing |
| KYMERA THERAPEUTICS INC KYMR | $8.0m2.28% | First filing |
| VOR BIOPHARMA INC COM | $7.3m2.09% | First filing |
| ENANTA PHARMACEUTICALS INC ENTA | $5.6m1.61% | First filing |
| OYSTER PT PHARMA INC OYST | $5.6m1.59% | First filing |
| IMMUNOCORE HLDGS PLC IMCR | $4.6m1.31% | First filing |
| ESPERION THERAPEUTICS INC NE ESPR | $4.2m1.20% | First filing |
| GRACELL BIOTECHNOLOGIES INC SPONSORED ADS | $3.3m0.94% | First filing |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| OLEMA PHARMACEUTICALS INC OLMA · 13G · filed 2025-02-14 | 10.0%≈ $92.9m |
| EDGEWISE THERAPEUTICS INC EWTX · 13G · filed 2026-08-14 | 9.5%≈ $415.1m |
| ACHIEVE LIFE SCIENCES INC ACHV · 13G · filed 2026-04-24 | 9.2%≈ $64.7m |
| ASSEMBLY BIOSCIENCES INC ASMB · 13G · filed 2026-08-14 | 7.8%≈ $42.7m |
| VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 | 6.1%≈ $123.5m |
| TYRA BIOSCIENCES INC TYRA · 13G · filed 2026-09-17 | 5.8%≈ $110.9m |
| LEXEO THERAPEUTICS INC LXEO · 13G · filed 2026-08-14 | 5.3%≈ $19.4m |
| MBX BIOSCIENCES INC MBX · 13G · filed 2026-06-24 | 5.2%≈ $137.6m |
| SPYRE THERAPEUTICS INC SYRE · 13G · filed 2026-10-01 | 5.1%≈ $395.7m |
| JADE BIOSCIENCES INC JBIO · 13G · filed 2026-07-17 | 5.1%≈ $69.0m |